ADMA BiologicsADMA
About: ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
Employees: 624
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
2,302% more call options, than puts
Call options by funds: $12.7M | Put options by funds: $527K
176% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 21
72% more capital invested
Capital invested by funds: $1.18B [Q1] → $2.02B (+$846M) [Q2]
17% more funds holding
Funds holding: 213 [Q1] → 250 (+37) [Q2]
6% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 83
0% more funds holding in top 10
Funds holding in top 10: 6 [Q1] → 6 (+0) [Q2]
0.14% less ownership
Funds ownership: 78.1% [Q1] → 77.96% (-0.14%) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
HC Wainwright & Co. Raghuram Selvaraju 56% 1-year accuracy 133 / 239 met price target | 16%upside $18 | Buy Reiterated | 14 Oct 2024 |
Cantor Fitzgerald Kristen Kluska 60% 1-year accuracy 47 / 78 met price target | 29%upside $20 | Overweight Reiterated | 20 Sept 2024 |
HC Wainwright & Co. Raghuram Selvaraju 56% 1-year accuracy 133 / 239 met price target | 16%upside $18 | Buy Maintained | 12 Aug 2024 |
Cantor Fitzgerald Kristen Kluska 60% 1-year accuracy 47 / 78 met price target | 29%upside $20 | Overweight Maintained | 9 Aug 2024 |
Financial journalist opinion
Based on 72 articles about ADMA published over the past 30 days
